Evaluation of Biomarkers and Surrogate Endpoints in Chronic Disease

Many people naturally assume that the claims made for foods and nutritional supplements have the same degree of scientific grounding as those for medication, but that is not always the case. The IOM recommends that the FDA adopt a consistent scientific framework for biomarker evaluation in order to...

Full description

Saved in:
Bibliographic Details
Main Authors Ball, John R, Micheel, Christine M
Format eBook
LanguageEnglish
Published Washington, D.C National Academies Press 07.05.2010
Edition1
Subjects
Biochemical markers
Biological Markers
Chronic Disease
Chronic diseases
Evaluation
Evidence-Based Practice
Online AccessGet full text

Cover

Table of Contents:
  • FrontMatter -- Reviewers -- Preface -- Acknowledgments -- Contents -- Boxes, Figures, and Tables -- Summary -- 1 Introduction -- 2 Review: Evaluating and Regulating Biomarker Use -- 3 The Biomarker Evaluation Process -- 4 Case Studies -- 5 Strengthening Evidence-Based Regulation -- Acronyms -- Glossary -- Appendix A: Table of Papers About Biomarker Qualification -- Appendix B: Recommendations from Related IOM Reports -- Appendix C: Committee Member and Consultant Biographies -- Appendix D: Staff Biographies -- Appendix E: Workshop Agenda -- Appendix F: Speaker Biographies